J2H-1701(J2H-1701) - 在研适应症：丙型肝炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制-

治疗领域

感染消化系统疾病

在研适应症

丙型肝炎

非在研适应症-

原研机构

J2H Biotech, Inc.

在研机构

J2H Biotech, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 J2H-1701 相关的临床结果

登录后查看更多信息

100 项与 J2H-1701 相关的转化医学

登录后查看更多信息

100 项与 J2H-1701 相关的专利（医药）

登录后查看更多信息

1

项与 J2H-1701 相关的文献（医药）

2021-01-01·Journal of Enzyme Inhibition and Medicinal Chemistry2区 · 医学

RETRACTED ARTICLE: Thiophen urea derivatives as a new class of hepatitis C virus entry inhibitors

2区 · 医学

ArticleOA

作者: Windisch, Marc ; Lim, Jee Woong ; Ryu, Hyung Chul ; Lee, Eun Kyu ; Choi, Inhee ; Kim, Tae Kon ; Yoo, Hye Hyun

To develop unique small-molecule inhibitors of hepatitis C virus (HCV), thiophen urea (TU) derivatives were synthesised and screened for HCV entry inhibitory activities. Among them, seven TU compounds exhibited portent anti-viral activities against genotypes 1/2 (EC₅₀ < 30 nM) and subsequently, they were further investigated; based on the pharmacological, metabolic, pharmacokinetic, and safety profiles, J2H-1701 was selected as the optimised lead compound as an HCV entry inhibitor. J2H-1701 possesses effective multi-genotypic antiviral activity. The docking results suggested the potential interaction of J2H-1701 with the HCV E2 glycoprotein. These results suggest that J2H-1701 can be a potential candidate drug for the development of HCV entry inhibitors.

100 项与 J2H-1701 相关的药物交易

登录后查看更多信息